Case Control in Sarcopenia Among Elderly Type 2 Diabetic Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: muscle ultrasound.
- Who it may be relevant to
- Registry conditions: Sarcopenia. Basic parameters: from 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Asessment of Sarcopenia Among Elderly Type 2 Diabetic Patients
Overview
1. Assess sarcopenia prevalence in elderly diabetic patients. 2. Evaluate impact of diabetes and its medications on muscle health. 3. detect effect of sacropenia on quality of life on elderly
Interventions
- Diagnostic test muscle ultrasound
Bedside muscle ultrasound to measure muscle thickness, cross-sectional area and echogenicity
Primary outcome measures
- Prevalence of sarcopenia assessed by muscle ultrasound in elderly diabetic [Time frame: Within 6 months from the start of recruitment.]
- Assessment of muscle strength using handgrip dynamometry [Time frame: Within 6 months]
Secondary outcome measures (1)
- Quality of life score using the SarQoL questionnaire. [Time frame: Within 6 months.]
Eligibility criteria
- Inclusion criteria:
The study will included all patient ,age ≥ 60 years,diagnosed with type 2 diabetes mellitus at least 5 years duraation according to ADA guideline referance(8) (diabetes can be made if a patient's A1C is 6.5% or higher, their FPG is 126 mg/dL or higher, or their 2-hour plasma glucose during an OGTT is 200 mg/dL or higher. A random plasma glucose of 200 mg/dL or higher, in conjunction with classic symptoms of hyperglycemia, also indicates diabetes)
●Able to give informed consent
- Exclusion criteria:
- chronic renal disease
- chronic liver disese
- Severe cognitive impairment
- Known neuromuscular diseases affecting mobility
- malignancy Data of the study will collected over one year duration from 1/2026 \_1/2027
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Feng L, Gao Q, Hu K, Wu M, Wang Z, Chen F, Mei F, Zhao L, Ma B. Prevalence and Risk Factors of Sarcopenia in Patients With Diabetes: A Meta-analysis. J Clin Endocrinol Metab. 2022 Apr 19;107(5):1470-1483. doi: 10.1210/clinem/dgab884. PMID 34904651
Identifiers
NCT: NCT07244601 · sarcopenia in elderly diabetic